The Use of Recombinant Factor VIII Products in Previously Treated Patients with Hemophilia A: Pharmacokinetics, Efficacy, Safety, and Inhibitor Development

ABSTRACT

Studies in previously treated patients (PTPs) have been conducted for the three recombinant factor VIII (rFVIII) concentrates currently licensed. Kogenate℗ has shown a recovery of 2.7% per IU/kg and a half-life of 15.8 hours. A prospective 5-year study in 58 patients showed that 82% of bleeds resolved with one treatment; the average dose was 25 IU/kg. For Recombinate®, the recovery was 2.4% per IU/kg and the half-life was 14.7 hours. In 69 patients, the average dose used to treat a bleed was 27.5 IU/kg, and 91% of responses were categorized as good or excellent. B-domain depleted rFVIII, Refacto℗, has shown a recovery of 2.7% per IU/kg and a half-life of 14 hours. In 113 PTPs, the average dose used was 29.5 IU/kg, and 71% of bleeds responded to one treatment. All three recombinant products have been shown to be safe and effective in very similar dosing regimens. In view of the good recoveries, it is probable that smaller doses, such as 20 IU/kg, could be recommended to treat a bleed effectively with one dose, given that dosing regimens were previously established using intermediate products. Clearly, this would have considerable financial advantages.

KEYWORDS

Recombinant factor VIII - recovery - half-life - dose - cost

REFERENCES

• 1 Gitschier J, Wood W I, Goralka T M. Characterization of the human factor VIII gene.  Nature . 1984;  312 326-330
• 2 Toole J T, Knopf J L, Wozney J M. Molecular cloning of a cDNA encoding human antihaemophilic factor.  Nature . 1984;  312 342-347
• 3 Vehar G A, Keyt B, Eaton D. Structure of human factor VIII.  Nature . 1984;  312 337-342
• 4 Wood W I, Capon D J, Simonsen C C. Expression of active human factor VIII from recombinant DNA clones.  Nature . 1984;  312 330-337
• 5 Schwartz R S, Abilgaard C F, Aledort L M. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.  N Engl J Med . 1990;  323 1800-1805
• 6 Giles A R, Tinlin S, Hoogendoorn H. In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).  Blood . 1988;  72 335-339
• 7 Seremetis S, Lusher J M, Abildgaard. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The Kogenate℗ Study Group.  Haemophilia . 1999;  5 9-16
• 8 Mannucci P M, Brettler D B, Aledort L M. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate℗ Study Group.  Blood . 1994;  83 1958-1962
• 9 Kaufman R J, Wasley L C, Dorner A J. Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells.  J Biol Chem . 1988;  263 6352-6362
• 10 Kaufman R J, Wasley L C, Davies M V. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.  Mol Cell Biol . 1989;  9 1233-1239
• 11 White G C, McMillan C W, Kingdon H S, Shoemaker C B. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.  N Engl J Med . 1989;  320 166-170
• 12 White G C, Courter S, Bray G L. A multicentre study of recombinant factor VIII (Recombinate™) in previously treated patients with haemophilia A. The Recombinate Previously Treated Patient Study Group.  Thromb Haemost . 1997;  77 660-667
• 13 Lind P, Larsson K, Spira J. Novel forms of B-domain deleted recombinant factor VIII molecules. Construction and biochemical characterizaton.  Eur J Biochem . 1995;  232 19-27
• 14 Schulman S. B-domain deleted human recombinant factor VIII.  Haemophilia . 1999;  7 5-10
• 15 Fijnvandraat K, Berntorp E, ten Cate W J. Recombinant, B-domain deleted factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients.  Thromb Haemost . 1997;  77 298-302
• 16 Kessler C M, Spira J, Magill M. Safety and efficacy of a second generation, B-domain deleted recombinant factor VIII (9r-VIII SQ) in previously treated patients (PTPs). A four year update.  Blood (Abst) . 1998;  92(Suppl 1) 555A
• 17 Aronstam A, Kirk P J, McHardy J. Twice weekly prophylactic therapy in haemophilia A.  J Clin Pathol . 1977;  30 65-67
• 18 Allain J-P. Dose requirements for replacement therapy in hemophilia A.  Thromb Haemost . 1979;  42 825-831
• 19 Aledort L M, Haschmeyer R H, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group.  J Intern Med . 1994;  236 391-399